GFAP and chronic kidney disease: Plasma levels of GFAP, NfL, Aβ42, and p‐tau231 significantly differed across individuals grouped by eGFR‐based CKD stage, such that as kidney function decreased, plasma biomarker levels increased despite statistically adjusting for potential confounders like age, race/ethnicity, and cognitive status.